Personal information

Other IDs

ResearcherID: P-6736-2017
SciProfiles: 465177

Countries

Saudi Arabia

Activities

Collapse all

Works (9)

Under Recognized Respiratory Tract Infections in Non-Neutropenic Fever Children with Cancer: Real-World Insights from Mass Religious Gatherings and Influenza Seasons

Journal of Pharmaceutical Research International
2022-12-06 | Journal article | Author
DOI: 10.9734/jpri/2022/v34i55a7244
Part of ISSN: 2456-9119
Contributors: Aeshah AlAzmi ; Wasil Jastaniah; Mona AlDabbagh; Naglla Elimam; Mohammed AlHindi
Source: Self-asserted source
Aeshah AlAzmi

A clinical approach to non-neutropenic fever in children with cancer

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Anthracycline-induced cardiac toxicity: A clinical review

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Coping with the residency program during COVID-19: Hematology oncology pharmacy residents’ perspective

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Epidemiology of Preventable Drug-Related Problems (DRPs) Among Hospitalized Children at KAMC-Jeddah: a Single-Institution Observation Study

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Evaluation of handling, storage, and disposal practices of oral anticancer medications among cancer patients and their caregivers at home setting in the Princess Noorah Oncology Center

Journal article
Source: Self-asserted source
Aeshah AlAzmi

FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Off-Label Drug Use in Pediatric Out-Patient Care: A Multi-Center Observational Study

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations

Journal article
Source: Self-asserted source
Aeshah AlAzmi

Peer review (1 review for 1 publication/grant)

Review activity for PloS one. (1)
How many people are using ORCID?